PACB Pacific Biosciences of California, Inc.
Healthcare$1.26+3.28%ClosedMarket Cap: $391.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
157.69
P/S
2.37
EV/EBITDA
-7.01
DCF Value
$-10.79
FCF Yield
-30.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
37.1%
Operating Margin
-101.7%
Net Margin
-80.3%
ROE
-488.4%
ROA
-16.4%
ROIC
-22.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $37.2M | 34.5% | $-37.9M | $-8.3M | $— | — |
| Q4 null | $44.6M | 37.5% | $-41.2M | $-40.4M | $— | — |
| FY null | $160.0M | 31.7% | $-557.6M | $-546.4M | $— | — |
| Q3 null | $38.4M | 39.2% | $-38.8M | $-38.0M | $— | — |
| Q2 null | $39.8M | 36.9% | $-44.9M | $-41.9M | $— | — |
| Q1 null | $37.2M | -3.7% | $-428.9M | $-426.1M | $— | — |
| Q4 null | $39.2M | 25.6% | $-153.0M | $2.4M | $— | — |
| FY null | $154.0M | 24.2% | $-474.3M | $-309.9M | $— | — |
| Q3 null | $40.0M | 25.0% | $-64.1M | $-60.7M | $— | — |
| Q2 null | $36.0M | 16.5% | $-175.8M | $-173.3M | $— | — |
| Q1 null | $38.8M | 29.1% | $-81.4M | $-78.2M | $— | — |
| Q4 2023 | $58.4M | 16.4% | $-87.5M | $-82.0M | $-0.31 | — |